The mRNA vaccines (RVs) can reduce the severity and mortality of severe acute respiratory
syndrome coronavirus (SARS-CoV-2). However, almost only the inactivated vaccines (IVs) …

Anti-viral immunity continuously declines over time after SARS-CoV-2 infection. Here, we
characterize the dynamics of anti-viral immunity during long-term follow-up and after …

As the COVID-19 pandemic continues, the authorization of vaccines for emergency use has
been crucial in slowing down the rate of infection and transmission of the SARS-CoV-2 virus …

Introduction: We compared the early total spike antibody (S-Ab) and neutralizing antibody (N-
Ab) responses to two vaccines. Methods: We studied 96 Pfizer and 34 Sinovac vaccinees …

Comparative studies of SARS-CoV-2 antinucleocapsid (anti-N) antibody response in the
context of inactivated virus vaccines versus natural infection are limited. This study aims to …

Two mRNA vaccines (BNT162b2 and mRNA-1273) against severe acute respiratory
syndrome-coronavirus 2 (SARS-CoV-2) are globally authorized as a two-dose regimen …

Understanding vaccine-mediated protection against severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) is critical to overcoming the global coronavirus disease 2019 …

Objectives In the context of the Covid-19 pandemic, the fast development of vaccines with
efficacy of around 95% preventing Covid-19 illness provides a unique opportunity to reduce …

Background SARS-CoV-2 vaccination has proven the most effective measure to control the
COVID-19 pandemic. Booster doses are being administered with limited knowledge on their …

How do we measure vaccine efficacy? The strictest but also easiest parameter to determine
vaccine efficacy is its ability to block infection. Indeed, if a vaccine is able to block infection …